RAUMATIC brain injury results in brain damage due to early cell death caused by shear stress or in delayed cell death due to secondary injury factors such as brain edema, BBB breakdown, and cerebral ischemia. Various pathophysiological mechanisms underlying these secondary injury factors have been hypothesized and are the basis of proposed therapeutic interventions to prevent serious late sequelae of TBI. Of these pathophysiological mechanisms, the breakdown of membrane phospholipids and the subsequent release of FFAs takes place immediately after both ischemic injury and TBI.
Male Sprague-Dawley rats each weighing 250 to 300 g were given 4% halothane to induce anesthesia and 1.5% halothane in a mixture of 50% nitrous oxide/50% oxygen to maintain it. Traumatic brain injury was induced using a CCI device similar to one developed and described earlier. 2, 6 After each animal was placed in a stereotactic frame, a craniectomy 6 mm in diameter was performed midway between the bregma and the lambda. The dura was kept intact and care was taken not to cause any injury to vascular structures. Each rat in the experimental groups was injured by a CCI device, which had a 5-mm-diameter tip traveling at a velocity of 3 m/second and creating a 2-mm-deep deformation; rats in the shamoperated group were subjected to the same surgical procedure, including craniectomy, but received no cortical impact. The exposed cortex was covered with Surgicel after TBI and the wound was closed with No. 3.0 silk sutures. All animals were allowed to recover from anesthesia, returned to their cages, and allowed free access to standard laboratory food and water. Core and cranial temperatures were monitored using rectal and temporal muscle probes, respectively, in all animals and maintained at ranges of 37 to 38˚C for rectal and 36 to 37˚C for temporal muscle temperatures by using a heating pad and lamp during the experiments.
In another group of 25 animals (sham-operated controls, salinetreated rats, and rats treated with 50-, 100-, or 400-mg/kg doses of CDPC [five animals in each group]), the left femoral artery was cannulated using a 22-gauge catheter (vascular access Intracath; Becton-Dickinson, Sandy, UT) for continuous monitoring of MABP and arterial blood gas levels after induction and maintenance of anesthesia, as mentioned previously. Blood gas concentrations and hematocrit levels in heparinized blood samples (0.15 ml) were measured using a portable blood gas analyzer (I-STAT; Sensor Devices, Inc., Waukesha, WI).
Wet-Dry Method for Brain Edema Measurements
Brain tissue water content, an indicator of brain edema, was measured 24 hours after injury. After the animal was anesthetized according to the same regimen specified earlier, it was killed, the brain was removed, and the left parietal cortex (injury site), contralateral right cortex, and ipsilateral left and contralateral right hippocampi were dissected (Fig. 1) . Dissected tissues were placed on preweighed glass tubes and weighed to yield wet weight. After the tissues had been dried by placing them in a desiccation oven at 70˚C for 48 hours, they were reweighed to determine water content. Water content is expressed as a percentage of H 2 O; this was calculated as ([wet weight Ϫ dry weight]/wet weight) ϫ 100.
Measurement of Extravasated EBD for BBB Integrity
Permeability to EBD was evaluated 6 hours after injury according to the method described earlier. 2, 19 Evans blue dye (2% in saline, 3 ml/kg) was administered intravenously and allowed to circulate for 60 minutes. To remove the intravascular dye, the animals were perfused with saline through the left ventricle at 100 cm H 2 O until colorless perfusion fluid was obtained from the right atrium. After decapitation of the rats, the brains were removed, and tissue samples from each of the four brain regions to be studied were removed (Fig.  1 ). Each tissue sample was weighed, homogenized in 2 ml of 50% trichloroacetic acid (wt/vol), and centrifuged at 10,000 rpm for 20 minutes. Evan's blue dye was extracted from the tissue by using 50% trichloroacetic acid to dissociate the dye from protein. After centrifugation, the supernatants containing EBD were diluted fourfold with ethanol. For fluorescence measurement, an aliquot was diluted with solvent (50% trichloroacetic acid/ethanol, 1:3). Tissue levels of EBD were quantitated using a spectrofluorometer at an excitation wavelength of 620 nm and an emission wavelength of 680 nm. Sample values were compared with those of EBD standards mixed with the solvent (100-1000 ng/ml). Results were expressed in micrograms of EBD per gram of tissue as the means Ϯ SD.
Experimental and Treatment Protocols
Animals were randomly assigned to be sham-operated controls, injured animals treated with saline, or injured animals treated with a CDPC dose of 50, 100, or 400 mg/kg. Saline in a volume of 0.5 ml or CDPC dissolved in 0.5 ml of saline was injected intraperitoneally two times after injury. The first treatment was given 5 minutes after injury in all animals. An additional treatment was given 4 hours after injury in animals in which EBD extravasation was evaluated and 6 hours after injury in animals in which brain edema measurements were made. These time points were chosen on the basis of previous studies, including ours, that showed formation of brain edema and BBB breakdown peaks 24 and 6 hours after experimental TBI, respectively. 2 
Statistical Analysis
Data are expressed as the means Ϯ SD. Statistical analysis of data was performed using one-way analysis of variance followed by Tukey's multiple-comparison posttest. A probability value less than 0.05 was considered statistically significant.
Results

Physiological Variables
Physiological variables for the sham-operated controls and injured animals treated with saline or CDPC are presented in Table 1 . The surgical procedure did not affect MABP in any animal, including sham-operated control animals. However, the MABP dropped significantly in all animals after injury. This decrease lasted for 1 minute, after which MABP completely recovered in 10 minutes (Table 2 ). This is a known effect of CCI brain injury on MABP in rats. 2 There were no statistically significant differences in physiological variables among the treatment groups during the procedure.
Brain Edema
Traumatic brain injury induced a significant increase in the percentage of water content in the injured cortex and ipsilateral hippocampus (82.2 Ϯ 0.7% compared with 78.6 Ϯ 0.9% in the ipsilateral and contralateral cortices, respectively, and 82.1 Ϯ 0.4% compared with 79.1 Ϯ 0.9% in the ipsilateral and contralateral hippocampi, respectively; p Ͻ 0.05) (Fig. 2) . Treatment with 50 mg/kg CDPC did not show any protective effect on brain edema (Fig. 2) . Compared with the saline-treated group, at a dose of 100 mg/kg CDPC reduced the percentage of water content only in the injured cortex (82.2 Ϯ 0.7% compared with 81 Ϯ 0.5; p Ͻ 0.05). Compared with the saline-treated group, a 400-mg/kg dose of CDPC significantly reduced the percentage of water content in both the injured cortex and the ipsilateral hippocampus (cortex 82.2 Ϯ 0.7% compared with 80.9 Ϯ 0.7%; hippocampus 82.1 Ϯ 0.4% compared with 81 Ϯ 0.6%; p Ͻ 0.05).
Blood-Brain Barrier Breakdown
Traumatic brain injury induced a significant increase in EBD extravasation in the injured cortex and ipsilateral hippocampus (157.1 Ϯ 28.3 g/g tissue compared with 9.5 Ϯ 5.6 g/g tissue in the injured and contralateral cortices, respectively, and 40.1 Ϯ 16.1 g/g tissue compared with 7.2 Ϯ 2 g/g tissue in the ipsilateral and contralateral hippocampi, respectively; p Ͻ 0.05) (Fig. 3) . A 50-mg/ kg dose of CDPC had no effect on EBD extravasation in the cortex and hippocampus. At doses of 100 and 400 mg/ kg, CDPC attenuated EBD extravasation in both the injured cortex and the ipsilateral hippocampus (cortex, from
in animals treated with saline to 14.3 Ϯ 6.1 and 23.9 Ϯ 19 g/g tissue in animals treated with 100 and 400 mg/kg CDPC, respectively; p Ͻ 0.05) (Fig. 3) .
Discussion
The results of this study show for the first time that CDPC reduces brain edema and BBB breakdown in not only the injured cortex, but also the hippocampus in this model of brain injury in rats. In the present study, CCI brain injury induced significant BBB breakdown and brain edema formation in the injured cortex and the ipsilateral hippocampus. Postinjury administration of CDPC provided significant neuroprotection in a dose-dependent manner in these brain regions. Of these regions, the hippocampus is particularly important because of its selective vulnerability to ischemic changes, even after mild-tomoderate brain injury.
Secondary Injury Factors After Brain Injury
Secondary injury factors, including posttraumatic brain edema and ischemia, are of great importance in patient outcome after head injury. Under a variety of pathological conditions such as TBI, a disruption of the BBB causes vasogenic brain edema. The essential events in the development of vasogenic edema are increased cerebrovascular permeability, enhanced driving forces that induce a bulk flow into the interstitial space, and retention of fluid.
1,11
The mechanism by which brain edema is formed after TBI
is not yet well defined. Edema formation might be directly related to the injury itself or to the secondary metabolic injury triggered by resultant local cerebral ischemia. Secondary metabolic injury is caused by the upregulation, release, or induction of a number of potentially damaging endogenous neurochemical factors. 12 One of these events is the breakdown of membrane phospholipids, which results in release of FFAs including arachidonic acid. Accumulation of arachidonic acid and its vasoactive metabolites, which includes the prostaglandins and leukotrienes, induces brain edema. 4 Furthermore, oxygen free radicals produced during arachidonic acid metabolism are also major contributors to cerebrovascular injury after TBI and cerebral ischemia.
Pharmacological Properties and the Neuroprotective Effects of CDPC
Cytidine 5Ј-diphosphocholine is a key intermediary in the biosynthesis of phosphatidylcholine, an important phospholipid component of cell membranes. When administered exogenously, CDPC is hydrolyzed in the intestine and in the circulation to form choline and cytidine. 17 Later, these two components disperse widely, cross the BBB, and reach the central nervous system, where they are incorporated into the phospholipid fraction of the membrane and microsomes. 17 Cytidine and choline also contribute to metabolic functions such as the formation of nucleic acids, proteins, and ACH.
Restoration of the phosphotransferase reaction by CDPC has been shown to prevent the release of FFAs after ischemic brain injury and to help remove diacylglycerol by changing it into phosphatidylcholine. 8 After transient global ischemia in gerbils and rats, CDPC has been shown to reduce the release of FFAs as well as prevent the decrease of phosphatidylcholine. 8, 18 Cytidine 5Ј-diphosphocholine also restores disrupted cerebral mitochondrial lipid metabolism induced by hypoxic-ischemic injury and attenuates lactate production. 9 In focal ischemia-reperfusion injury, long-term administration of a dose of 500 mg/ kg CDPC reduced infarction size and improved neurological outcome in rats. 16 In spite of experimental evidence in cerebral ischemia that shows the neuroprotective effects of CDPC, there are limited reports regarding its neuroprotective effects on TBI. In a recent study in which the CCI brain injury model was used, Dixon, et al., 7 showed that delayed posttraumatic administration of CDPC attenuated functional deficits 18 days after injury. They also found, for the first time, that in microdialysis studies 100 mg/kg of CDPC increased ACH in the hippocampus. Rao and associates 14 demonstrated that CDPC protects CA1 neurons in the gerbil hippocampus 6 days after reperfusion injury. double-blind, placebo-controlled, randomized, dose-ranging study has demonstrated favorable outcome at 90 days postinjury in patients with focal ischemic stroke. 3 Many different mechanisms have been shown to induce secondary injury after stroke or TBI. Polypharmaceutical or combinational drug therapy is becoming a viable option for future treatment of brain injury. 12 Cytidine 5Ј-diphosphocholine has been combined with MK-801, a noncompetitive N-methyl-D-aspartate receptor antagonist and a basic fibroblast growth factor to reduce infarction size after focal ischemia. 13, 15 In both studies, combination therapy was synergistically effective in reducing infarction size and improving neurological deficits. 13, 15 On the other hand, an alternative option to combination therapy might be a single protective agent such as CDPC, which may act through more than one mechanism.
Conclusions
The present study is the first to demonstrate neuroprotective effects of CDPC on secondary injury factors, brain edema and BBB breakdown, in the injured cortex and hippocampus after CCI brain injury in rats. Because it appears that CDPC may exert neuroprotective effects through different pathways and favorable outcome with CDPC has been shown after ischemic stroke, we believe that it may be an ideal agent for future treatment strategies.
